Dr. Antje Behring graduated with a PharmD and PhD in pharmaceutical science from the University of Munich, Germany. After working as consulting pharmacist for a German health insurance company, she joined Germany’s Federal Joint Committee (Gemeinsamer Bundesausschuss) Pharmaceuticals Department. Since then she has been involved in introduction of the procedure for additional benefit assessments for new pharmaceutical products and is responsible for handling incoming dossiers and requests for consultation meetings with pharmaceutical companies concerning the additional benefit assessment.
Appearing:
Day Two Thursday 6th October 2011
4.30pm
Germany: Latest developments in pricing and reimbursement
Role of G-BA in drug regulation in Germany
Obligatory dossier on benefit and costs with market launch